Superior bioavailability of digoxin solution in capsules.
The bioavailability of various formulations of digoxin was assessed after single and multiple doses in a series of crossover studies in human volunteers. Digoxin tablets that were 97% dissolved in 1 hr in vitro were not significantly better absorbed than tablets with a dissolution rate of 78%. A solution given in capsule form had greater bioavailability than tablets of 97% dissolution rate; serum and urinary glycoside levels after 0.4 mg doses of the encapsulated solution were similar to those attained after 0.5 mg doses of tablets with dissolution rates of 78% and 97%. The bioavailability of the solution in capsule form exceeded that of equal doses of the same solution given as a liquid or that of a standard elixir. No increase in gastrointestinal or cardiac toxicity was detected. Inter- and intrasubject variation in bioavailability was not decreased. Above a certain level, dissolution rate is no longer the limiting factor in digoxin absorption. The mechanism of the enhanced bioavailability of concentrated liquid digoxin in capsule form remains to be determined. Such a preparation deserves further consideration as a possible replacement for digoxin tablets.
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001682:Biological Availability; D002214:Capsules; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D012996:Solutions; D013607:Tablets; D013997:Time Factors
D002214:Capsules; D012996:Solutions; D013607:Tablets; D004077:Digoxin